Hypera S.A. (OTCMKTS:HYPMY - Get Free Report)'s stock price passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $3.50 and traded as high as $3.80. Hypera shares last traded at $3.80, with a volume of 249 shares trading hands.
Hypera Stock Up 2.4 %
The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.41 and a current ratio of 1.81. The business has a 50-day simple moving average of $3.50 and a two-hundred day simple moving average of $3.41. The company has a market capitalization of $2.41 billion, a price-to-earnings ratio of 15.83 and a beta of 0.76.
Hypera (OTCMKTS:HYPMY - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The company reported ($0.04) earnings per share (EPS) for the quarter. The firm had revenue of $184.34 million for the quarter. Hypera had a return on equity of 13.18% and a net margin of 20.04%.
About Hypera
(
Get Free Report)
Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hypera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hypera wasn't on the list.
While Hypera currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
